Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AgfiledCriticalBayer Healthcare Ag
Publication of CR9952ApublicationCriticalpatent/CR9952A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Pyridine Compounds
(AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Abstract
La presente invencion se refiere a composiciones farmaceuticas para el tratamiento, prevencion o gestion de la hipertension pulmonar que comprende al menos un agente terapeutico adicional. Combinaciones utiles incluyen, por ejemplo, BAY 43-9006 como un compuesto de diarilurea.The present invention relates to pharmaceutical compositions for the treatment, prevention or management of pulmonary hypertension comprising at least one additional therapeutic agent. Useful combinations include, for example, BAY 43-9006 as a diarylurea compound.
CR9952A2005-11-102008-05-06
DIARILURE FOR THE TREATMENT OF PULMONARY HYPERTENSION
CR9952A
(en)
DERIVATIVES OF 2,3-DIHYDROIMIDAZO [1,2-C] SUBSTITUTED QUINAZOLINE USEFUL FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISEASES ASSOCIATED WITH ANGIOGENESIS
Glucopyranosyl substituted 3-benzyl benzene derivative compounds; pharmaceutical composition; pharmaceutical combination comprising said compounds; and its use for the treatment or prevention of metabolic diseases such as diabetes, among others (divisional application 566-05).